New York, N.Y., June 18, 2013 -- Lauren Sciences, a privately-held biotechnology company furthering development of its novel V-Smart™ nanovesicle platform technology, announced today that it was independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in a new report by MCD Group.
The report, "Early Stage Drug Delivery Technologies: Profiles of Start-ups and Emerging Companies," features companies MCD Group independently selected as technology innovators that could potentially transform drug delivery in one or more therapeutic areas. Lauren Sciences was selected based on its groundbreaking work to-date in achieving delivery of a variety of drugs and biologics across the blood brain barrier (BBB). The MCD Group report includes an in-depth profile of Lauren Sciences, providing a scientific description of the V-Smart™ technology and detailed information on its V-Smart™ therapeutic programs in central nervous system (CNS) diseases such as Parkinson's disease, neuro-HIV and brain cancer.
"The inclusion of Lauren Sciences in the MCD Group report is yet another independent acknowledgement of the potential of Lauren Sciences and our innovative V-Smart™ drug delivery technology," said Susan Rosenbaum, J.D., Chairman and Chief Executive Officer of Lauren Sciences. "We expect that this recognition will foster new strategic partnerships within the pharmaceutical industry for Lauren Sciences and, thus, further development of transformative V-Smart™ therapeutics for CNS-disease patients."
About the V-Smart™ Platform
V-Smart™ is a platform technology that can be used for a variety of uses including delivery of therapeutic drugs. The V-Smart™ drug delivery system is based on novel nanovesicles that have unique superiority to other nanovesicles, such as liposomes. Major advantages of the V-Smart™ nanovesicles include: high stability, large encapsulation capacity of a variety of potential drugs (e.g., small molecules, peptides, proteins and nucleic acids), ability to transport the drugs across the BBB, targeting to specific cells and release of encapsulated drugs in a controlled manner at targeted sites.
About Lauren Sciences LLC
Lauren Sciences is a privately-held New York biotechnology company focused on developing its V-Smart™ platform to create a robust pipeline of V-Smart™ therapeutics consisting of central nervous system (CNS)-active drugs that normally do not cross the BBB. The company's lead program is for Parkinson's disease (supported by a grant awarded by The Michael J. Fox Foundation). Additional pipeline programs include other CNS disorders, such as neuro-HIV (supported by a grant awarded by The Campbell Foundation), Alzheimer's disease, GBM (brain cancer), ALS (Lou Gehrig's disease) and lysosomal storage diseases (LSDs), among others. The company's Chief Scientific Officer, Dr. Eliahu Heldman, is Professor Emeritus at Ben-Gurion University, Israel where he, with Dr. Sarina Grinberg and Dr. Charles Linder, developed the V-Smart™ technology and lead the Lauren Sciences research team. Dr. Irwin Hollander serves as the company's Vice President of Research and Development in New York.
MCD Group is an independent organization that provides clients with in-depth profiles of multiple innovative companies. Profiled companies are selected purely by MCD Group's independent assessment of their importance in the market under discussion. They alone decided that Lauren Sciences was worthy of inclusion in their report. Lauren Sciences did not approach MCD Group, had no influence or involvement in the decision or choice as to its inclusion and did not, and does not, receive any compensation therefor. Lauren Sciences has not read the aforementioned report and, therefore, cannot defend, or opine on, the contents therein.
Contact: Susan Rosenbaum, J.D., Lauren Sciences LLC, (917) 397-2826, email@example.com.